Company intelligence / Profile preview

Cansativa

Frankfurt am Main, Hessen, Germany

Ownership: Private
Employees: ~75
Development stage: Other

Overview

Cansativa is Germany’s largest distributor of medicinal cannabis with exclusive government contracts, over 500 SKUs, 40+ global suppliers, and direct access to 2,500 German pharmacies. In 2023, over 3,000 kg was distributed, with 75% of patients treated for pain. The clinical utility is established through broad patient access to regulated cannabis[2][5][6].

Therapeutic areas: OncologyNeurologyOther
Modalities: Small moleculePlant-derived therapeutic
Industry: Biotech

Partnerships

Cronos Inc. (Peace Naturals brand)MedMenOver 40 international suppliers[5]

Beyond the preview

Go deeper on Cansativa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cansativa.

Explore the full profile